No Data
No Data
Hong Kong Stocks News | Kangnova-B (02162) rose more than 5%. The exploratory clinical study results of CM313 for the treatment of adult ITP were announced recently.
According to the Smart Finance App, Connoah-B (02162) is now up more than 5%, as of press time, up 5.61%, at HK$34.85, with a turnover of HK$8.6435 million. In terms of news, Connoah announced that Zhang Lei's team from the Institute of Hematology of the Chinese Academy of Medical Sciences recently published a research paper titled A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia in The New England Journal of Medicine. This is an initiative by researchers.
Conybio-B (02162.HK): The exploratory clinical study of CM313 for the treatment of primary immune thrombocytopenia (ITP) in adults was recently published in the New England Journal of Medicine.
On June 20th, Galenpharm announced that the team led by Zhang Lei at the Hematology Research Institute of the Chinese Academy of Medical Sciences recently published a research paper titled A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia in the New England Journal of Medicine. This is a initiated, single-arm, open-label, exploratory clinical study designed to evaluate the safety of CM313 in treating adult primary immune thrombocytopenia patients.
Hong Kong stock market abnormal movement: Connoah-B (02162) is now up nearly 5%. Sipuleucel-T injection, a pharmaceutical, has been accepted for listing approval. CM310 is expected to be approved by the end of the year.
Connoya-B (02162) is now up nearly 5%. As of press time, it has risen 4.92% to HKD 35.2 with a turnover of HKD 16.2218 million.
Keymed Biosciences (HKG:2162) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems
HK stocks surge: Afternoon surge of nearly 5% in Cansino Biologics (02162); Simcere seeks injection of anti-PD-1 monoclonal antibody drug listing approval, application accepted by the National Medical Products Administration.
Kanoya-B (02162) rose nearly 5% in the afternoon. At the time of publication, it rose 4.46%, to HKD 35.15, with a turnover of HKD 16,130.3 million.
Keymed Biosciences' Rhinosinusitis Drug Gets NDA Application Acceptance From NMPA
Keymed Biosciences (HKG:2162) said its new drug application, Stapokibart injection, for the treatment of chronic rhinosinusitis with nasal polyps, has recently been accepted by China's National Medic
No Data